IL129407A0 - Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof - Google Patents

Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof

Info

Publication number
IL129407A0
IL129407A0 IL12940797A IL12940797A IL129407A0 IL 129407 A0 IL129407 A0 IL 129407A0 IL 12940797 A IL12940797 A IL 12940797A IL 12940797 A IL12940797 A IL 12940797A IL 129407 A0 IL129407 A0 IL 129407A0
Authority
IL
Israel
Prior art keywords
protease
virus
inhibitors
pharmaceutical compositions
same
Prior art date
Application number
IL12940797A
Other languages
English (en)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IL129407A0 publication Critical patent/IL129407A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL12940797A 1996-10-18 1997-10-17 Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof IL129407A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2829096P 1996-10-18 1996-10-18
PCT/US1997/018968 WO1998017679A1 (en) 1996-10-18 1997-10-17 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease

Publications (1)

Publication Number Publication Date
IL129407A0 true IL129407A0 (en) 2000-02-17

Family

ID=21842625

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12940797A IL129407A0 (en) 1996-10-18 1997-10-17 Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
IL129407A IL129407A (en) 1996-10-18 1999-04-13 Siren Protease Inhibitors Especially NS3 Viral Protease of Hepatitis C, Pharmaceutical Preparations Containing Them and Their Use
IL191905A IL191905A0 (en) 1996-10-18 2008-06-03 Inhibitors of serine proteases particularly hepatitis c virus ns3 protease, pharmaceutical compositions containing the same and the use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL129407A IL129407A (en) 1996-10-18 1999-04-13 Siren Protease Inhibitors Especially NS3 Viral Protease of Hepatitis C, Pharmaceutical Preparations Containing Them and Their Use
IL191905A IL191905A0 (en) 1996-10-18 2008-06-03 Inhibitors of serine proteases particularly hepatitis c virus ns3 protease, pharmaceutical compositions containing the same and the use thereof

Country Status (33)

Country Link
US (5) US6265380B1 (cg-RX-API-DMAC10.html)
EP (3) EP0932617B1 (cg-RX-API-DMAC10.html)
JP (3) JP4080541B2 (cg-RX-API-DMAC10.html)
KR (1) KR100509388B1 (cg-RX-API-DMAC10.html)
CN (1) CN1133649C (cg-RX-API-DMAC10.html)
AP (1) AP1019A (cg-RX-API-DMAC10.html)
AT (1) ATE212037T1 (cg-RX-API-DMAC10.html)
BG (1) BG103392A (cg-RX-API-DMAC10.html)
BR (1) BR9712544B1 (cg-RX-API-DMAC10.html)
CA (1) CA2268391A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ298749B6 (cg-RX-API-DMAC10.html)
DE (1) DE69709671T2 (cg-RX-API-DMAC10.html)
DK (1) DK0932617T3 (cg-RX-API-DMAC10.html)
EA (1) EA001915B1 (cg-RX-API-DMAC10.html)
EE (1) EE04023B1 (cg-RX-API-DMAC10.html)
ES (1) ES2169880T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20012471B (cg-RX-API-DMAC10.html)
HU (1) HU227742B1 (cg-RX-API-DMAC10.html)
ID (1) ID21649A (cg-RX-API-DMAC10.html)
IL (3) IL129407A0 (cg-RX-API-DMAC10.html)
IN (1) IN183120B (cg-RX-API-DMAC10.html)
IS (1) IS5028A (cg-RX-API-DMAC10.html)
MX (1) MXPA05003026A (cg-RX-API-DMAC10.html)
NO (2) NO329751B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ335276A (cg-RX-API-DMAC10.html)
PL (2) PL194025B1 (cg-RX-API-DMAC10.html)
PT (1) PT932617E (cg-RX-API-DMAC10.html)
SK (1) SK286105B6 (cg-RX-API-DMAC10.html)
TR (1) TR199901602T2 (cg-RX-API-DMAC10.html)
TW (1) TW530065B (cg-RX-API-DMAC10.html)
UA (2) UA79749C2 (cg-RX-API-DMAC10.html)
WO (1) WO1998017679A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA979327B (cg-RX-API-DMAC10.html)

Families Citing this family (354)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1852121A3 (en) 1994-08-29 2007-11-21 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
EP0932617B1 (en) 1996-10-18 2002-01-16 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9707659D0 (en) * 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
WO1999007733A2 (en) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
PT1012180E (pt) * 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
GB9806815D0 (en) * 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
ES2281170T3 (es) * 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
GB9809664D0 (en) 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
WO2001002424A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
AU6371900A (en) * 1999-07-26 2001-02-13 Du Pont Pharmaceuticals Company Lactam inhibitors of hepatitis c virus ns3 protease
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
AU2055301A (en) 1999-12-03 2001-06-12 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
DE60021282T2 (de) * 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
EP1261611A2 (en) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2006202124B2 (en) * 2000-04-03 2010-01-21 Vertex Pharmaceuticals Incorporated Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3 Protease
ATE297946T1 (de) 2000-04-03 2005-07-15 Vertex Pharma Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
CN1441806A (zh) 2000-04-05 2003-09-10 先灵公司 包含n－环p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
NZ521456A (en) 2000-04-19 2004-07-30 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA007867B1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
US20020007324A1 (en) * 2000-06-09 2002-01-17 Centner David J. System and method for effectively conducting transactions between buyers and suppliers
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CZ2003195A3 (cs) * 2000-07-21 2003-04-16 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
IL153670A0 (en) 2000-07-21 2003-07-06 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1430903A1 (de) * 2000-10-12 2004-06-23 Viromics Gmbh Verwendung von Proteasome Hemmern zur Behandlung von Virus-Infektionen
KR100905221B1 (ko) 2000-10-18 2009-07-01 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
WO2002048157A2 (en) * 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
WO2003006490A1 (en) 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
KR100871648B1 (ko) 2001-08-31 2008-12-03 톰슨 라이센싱 조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
MXPA04003825A (es) * 2001-10-24 2004-07-08 Vertex Pharma Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
MXPA04007163A (es) 2002-01-23 2004-10-29 Schering Corp Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c.
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7273885B2 (en) 2002-04-11 2007-09-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US6869964B2 (en) 2002-05-20 2005-03-22 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis C virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004032827A2 (en) * 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP1505945B1 (en) 2002-05-20 2008-11-05 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
CN104193791A (zh) 2002-06-28 2014-12-10 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
AU2003277891A1 (en) * 2002-09-23 2004-04-08 Medivir Ab Hcv ns-3 serine protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
TW200510391A (en) 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2004230946A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1620412A2 (en) 2003-05-02 2006-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic compounds and hydro isomers thereof
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
CN102020700A (zh) 2003-07-18 2011-04-20 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
JP4527722B2 (ja) 2003-08-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスの新規のペプチド模倣性ｎｓ３−セリンプロテアーゼインヒビター
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2004274468B2 (en) * 2003-09-18 2009-07-23 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2004274051A1 (en) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
EP1664092B1 (en) 2003-09-26 2011-02-02 Schering Corporation Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
TW200528472A (en) * 2003-10-10 2005-09-01 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
ES2398912T3 (es) 2003-10-14 2013-03-22 F. Hoffmann-La Roche Ltd. Ácido carboxílico macrocíclico y compuesto de acilsulfonamida como inhibidor de la replicación del virus de la hepatitis C
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
EP1678202B1 (en) 2003-10-27 2012-06-13 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN1902216A (zh) 2003-11-20 2007-01-24 先灵公司 丙肝病毒ns3蛋白酶的去肽化抑制剂
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
RS51243B (sr) 2004-01-30 2010-12-31 Medivir Ab. Inhibitori ns-3 serina hcv proteaze
EP1711515A2 (en) * 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ES2322602T3 (es) 2004-02-24 2009-06-23 Japan Tobacco, Inc. Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
CN1950393A (zh) 2004-02-27 2007-04-18 先灵公司 丙型肝炎病毒ns3蛋白酶的抑制剂
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
DK1730110T3 (da) 2004-02-27 2010-09-27 Schering Corp Svovlforbindelser som inhibitorer af hepatitis C-virus NS3-serinprotease
TW200602037A (en) 2004-02-27 2006-01-16 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
KR20060124729A (ko) 2004-02-27 2006-12-05 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의 억제제로서의신규한 화합물
HUE024556T2 (hu) * 2004-03-12 2016-02-29 Vertex Pharma Eljárások és intermedierek aszparagin acetál kapszáz inhibitorok elõállítására
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
AU2005238445B2 (en) 2004-04-15 2012-05-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
JP5108509B2 (ja) * 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
ES2328596T3 (es) 2004-05-20 2009-11-16 Schering Corporation Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c.
EP1778702B1 (en) * 2004-07-16 2011-07-13 Gilead Sciences, Inc. Antiviral compounds
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008511633A (ja) 2004-08-27 2008-04-17 シェーリング コーポレイション Ｃ型肝炎ウィルスｎｓ３セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
TW201300108A (zh) 2004-10-01 2013-01-01 Vertex Pharma Ｃ型肝炎病毒（ｈｃｖ）ｎｓ３-ｎｓ４ａ蛋白酶抑制劑
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1879879B1 (en) 2005-05-13 2013-03-27 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP1881828A4 (en) * 2005-05-20 2009-06-03 Valeant Res & Dev TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
WO2006130666A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
CA2611155A1 (en) 2005-06-02 2006-12-07 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
AR054778A1 (es) 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
BRPI0614242A2 (pt) 2005-07-29 2011-03-15 Medivir Ab inibidores macrocìclicos do vìrus da hepatite c, combinação e composição farmacêutica compreendendo os mesmos, bem como uso e processo para a preparação dos referidos inibidores
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
DK1912996T3 (da) 2005-07-29 2012-09-17 Janssen R & D Ireland Makrocykliske inhibitorer af hepatitis C-virus
BRPI0614696A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos de vìrus da hepatite c
ATE496042T1 (de) 2005-07-29 2011-02-15 Tibotec Pharm Ltd Makrocyclische inhibitoren des hepatitis-c-virus
ES2456617T3 (es) 2005-07-29 2014-04-23 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP5230417B2 (ja) 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大員環インヒビター
US20090325889A1 (en) * 2005-08-01 2009-12-31 David Alan Campbell Hepatitis c serine protease inhibitors and uses therefor
AU2006275413B2 (en) 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
DE602006013492D1 (de) 2005-08-19 2010-05-20 Vertex Pharma Verfahren und zwischenprodukte
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
EP1943228A2 (en) * 2005-10-11 2008-07-16 Intermune, Inc. Inhibitors of viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5436860B2 (ja) 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1951748B1 (en) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
NZ569293A (en) * 2005-12-23 2011-10-28 Zealand Pharma As Modified lysine-mimetic compounds
US20090304631A1 (en) * 2006-01-27 2009-12-10 David Alan Campbell Hepatitis c serine protease inhibitors and uses therefor
WO2007092616A2 (en) * 2006-02-09 2007-08-16 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
NZ571280A (en) * 2006-03-16 2011-10-28 Vertex Pharma Deuterated hepatitis C protease inhibitors
US7825152B2 (en) 2006-04-11 2010-11-02 Novartis Ag Organic compounds and their uses
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
AU2007253819B2 (en) 2006-05-23 2011-02-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2007149512A2 (en) 2006-06-19 2007-12-27 Proteolix, Inc. Peptide epoxyketones for pr0teas0me inhibition
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP2054076A2 (en) * 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
NZ575186A (en) * 2006-08-28 2012-03-30 Vertex Pharma Method for identifying protease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RS52874B (sr) 2006-11-15 2013-12-31 Vertex Pharmaceuticals Incorporated Analozi tiofena za lečenje ili prevenciju infekcija izazvanih flavivirusom
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010512317A (ja) 2006-12-07 2010-04-22 シェーリング コーポレイション ｐＨ感受性マトリクス処方物
DK2468724T3 (en) 2006-12-21 2016-02-22 Zealand Pharma As Synthesis of pyrrolidine compounds
WO2008082484A1 (en) 2006-12-22 2008-07-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
CN101611025A (zh) 2006-12-22 2009-12-23 先灵公司 5,6-环化的吲哚衍生物及其使用方法
WO2008082488A1 (en) 2006-12-22 2008-07-10 Schering Corporation 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
BRPI0807087A2 (pt) 2007-02-08 2014-06-10 Tibotec Pharm Ltd Inibidores de hcv macrocíclicos substituídos de pirimidina
CN101600428A (zh) * 2007-02-09 2009-12-09 Irm责任有限公司 作为通道活化蛋白酶抑制剂的化合物和组合物
AR065498A1 (es) * 2007-02-27 2009-06-10 Vertex Pharma Co- critales de vx-950 (un inhibidor del virus de la hepatitis c) y composiciones farmaceuticas que los comprenden
AU2008219704A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
ATE525068T1 (de) 2007-02-28 2011-10-15 Conatus Pharmaceuticals Inc Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2008248116A1 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
US8178491B2 (en) 2007-06-29 2012-05-15 Gilead Sciences, Inc. Antiviral compounds
CN101801925A (zh) 2007-06-29 2010-08-11 吉里德科学公司 抗病毒组合物
BRPI0816116A2 (pt) 2007-08-29 2015-03-03 Schering Corp Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
AU2008295484B2 (en) 2007-08-29 2013-09-26 Merck Sharp & Dohme Llc Substituted indole derivatives and methods of use thereof
TW200911807A (en) 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
AU2008297015B2 (en) * 2007-08-30 2013-08-22 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
MY173938A (en) * 2007-10-04 2020-02-27 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
CN102317285A (zh) 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
MX2010005356A (es) 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
BRPI0908021A2 (pt) 2008-02-04 2015-07-21 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102046648A (zh) 2008-05-29 2011-05-04 百时美施贵宝公司 丙型肝炎病毒抑制剂
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR072088A1 (es) 2008-06-13 2010-08-04 Schering Corp Derivados de indol triciclicos y sus metodos de uso
AU2009277172B2 (en) 2008-07-02 2014-05-29 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734489C (en) 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
CA2746004C (en) 2008-12-03 2017-06-06 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
BRPI0922364A2 (pt) 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8589372B2 (en) 2008-12-16 2013-11-19 Clinton A. Krislov Method and system for automated document registration with cloud computing
US8914351B2 (en) 2008-12-16 2014-12-16 Clinton A. Krislov Method and system for secure automated document registration from social media networks
UY32325A (es) * 2008-12-19 2010-07-30 Gilead Sciences Inc Inhibidores de ns3 proteasa del vhc
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
WO2010117936A1 (en) 2009-04-06 2010-10-14 Schering Corporation Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
WO2010117939A1 (en) 2009-04-06 2010-10-14 Schering Corporation Hcv inhibitor and therapeutic agent combinations
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
SI2477980T1 (sl) 2009-09-15 2017-01-31 Taigen Biotechnology Co., Ltd. Inhibitorji HCV proteaze
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
AU2010326225A1 (en) 2009-11-25 2012-06-07 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
CA2785300A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
EP2515902A1 (en) 2009-12-24 2012-10-31 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
CA2788155C (en) 2010-01-27 2018-04-24 AB Pharma Ltd. Polyheterocyclic compounds highly potent as hcv inhibitors
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
ES2558554T3 (es) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011119860A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
AU2011232331A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
JP2013522377A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
CA2794671C (en) 2010-03-31 2018-05-01 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2555621A4 (en) 2010-04-07 2014-07-02 Onyx Therapeutics Inc CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
CA2800509A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006055A2 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
CA2811799A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
RU2014102102A (ru) 2011-06-23 2015-07-27 Дигна Байотек, С.Л. КОМПОЗИЦИЯ И КОМБИНИРОВАННЫЙ ПРЕПАРАТ ИНТЕРФЕРОНА-а5 С ИНТЕРФЕРОНОМ-а2 И СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С
US20120328565A1 (en) 2011-06-24 2012-12-27 Brinkman John A Antiviral compounds
CN102807607B (zh) * 2011-07-22 2013-10-23 爱博新药研发(上海)有限公司 抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
AR087346A1 (es) 2011-07-26 2014-03-19 Vertex Pharma Formulaciones de compuestos de tiofeno
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
MX2014003705A (es) 2011-10-10 2014-07-22 Hoffmann La Roche Compuestos antivirales.
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MX2014006479A (es) 2011-11-30 2015-01-22 Univ Emory Inhibidores antivirales de la janus cinasa utiles en el tratamiento o prevencion de infecciones retrovirales y otras infecciones virales.
US9364484B2 (en) 2011-12-06 2016-06-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
CA2855574A1 (en) 2011-12-16 2013-06-20 F. Hoffmann-La Roche Ag Inhibitors of hcv ns5a
LT2794628T (lt) 2011-12-20 2017-07-10 Riboscience Llc 4`-azido-3`-fluoro pakeistieji nukleozido dariniai kaip hcv replikacijos inhibitoriai
UA111761C2 (uk) 2011-12-20 2016-06-10 Рібосаєнс Ллс 2',4'-дифтор-2'-метилзаміщені нуклеозидні похідні як інгібітори реплікації phk вірусу гепатиту c
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CA2858814A1 (en) 2012-01-12 2013-07-18 Rfs Pharma, Llc Hcv ns3 protease inhibitors
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
WO2013123456A1 (en) * 2012-02-16 2013-08-22 Rqx Pharmaceuticals, Inc. Linear peptide antibiotics
EP2817291A1 (en) 2012-02-24 2014-12-31 F. Hoffmann-La Roche AG Antiviral compounds
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MX355708B (es) 2012-05-22 2018-04-27 Idenix Pharmaceuticals Llc Compuestos de d-aminoacidos para enfermedades del higado.
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
AP2015008384A0 (en) 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2920195A1 (en) 2012-11-14 2015-09-23 IDENIX Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
RU2015132550A (ru) 2013-01-23 2017-03-02 Ф. Хоффманн-Ля Рош Аг Противовирусные производные триазола
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
JP6018715B2 (ja) 2013-03-05 2016-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ウイルス化合物
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
PE20160119A1 (es) 2013-05-16 2016-02-24 Riboscience Llc Derivados de nucleosido 4'-azido, 3'-desoxi-3'-fluoro sustituido
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
US9895442B2 (en) 2013-05-16 2018-02-20 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
JP2016528257A (ja) * 2013-08-14 2016-09-15 アールキューエックス ファーマシューティカルズ，インク． 直鎖ペプチド抗生物質
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
EP3113763A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CA3005551A1 (en) 2015-11-20 2017-05-26 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
JP7179721B2 (ja) 2016-06-21 2022-11-29 オリオン・オフサルモロジー・エルエルシー 複素環式プロリンアミド誘導体
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC CARBOCYCLIC PROLINAMIDE DERIVATIVES
WO2017222917A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Aliphatic prolinamide derivatives
WO2018036942A1 (en) * 2016-08-23 2018-03-01 F. Hoffmann-La Roche Ag New difluoroketamide derivatives as htra1 inhibitors
ES2870106T3 (es) 2017-05-05 2021-10-26 Zealand Pharma As Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
GB2563396B (en) * 2017-06-12 2020-09-23 Ustav Organicke Chemie A Biochemie Av Cr V V I Inhibitors of Rhomboid Intramembrane Proteases
SG11202002431SA (en) 2017-09-21 2020-04-29 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EP3891508A1 (en) 2018-12-04 2021-10-13 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
PL3968983T3 (pl) 2019-05-28 2024-03-18 F. Hoffmann-La Roche Ag Makrocykliczne antybiotyki o szerokim zakresie działania

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5496927A (en) 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
CA1341029C (en) * 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
DE3683541D1 (de) 1985-06-07 1992-03-05 Ici America Inc Selektionierte difluorverbindungen.
US5231084A (en) 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
NZ223148A (en) * 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
US4820691A (en) * 1987-06-24 1989-04-11 E. R. Squibb & Sons, Inc. Amino acid 1,2-diketo derivatives as renin inhibitors
EP0356595A1 (en) * 1988-09-01 1990-03-07 Merrell Dow Pharmaceuticals Inc. Novel peptidase inhibitors
US5736520A (en) 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
EP0371179A1 (en) * 1988-10-28 1990-06-06 Merrell Dow Pharmaceuticals Inc. Novel analogs of peptidase substrates
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
JPH0480541A (ja) * 1990-07-24 1992-03-13 Matsushita Seiko Co Ltd 加湿機
JP2668003B2 (ja) * 1992-06-12 1997-10-27 ファイザー インク． ヒトの心臓キマーゼを含むアンギオテンシンｉキマーゼに関する阻害剤
US5484410A (en) * 1992-06-24 1996-01-16 Science Incorporated Mixing and delivery system
US5371072A (en) 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
DE69329544T2 (de) * 1992-12-22 2001-05-31 Eli Lilly And Co., Indianapolis HIV Protease hemmende Verbindungen
DE69331643T2 (de) 1992-12-29 2002-10-31 Abbott Laboratories, Abbott Park Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5656600A (en) 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
EP0639585A1 (en) * 1993-08-20 1995-02-22 Banyu Pharmaceutical Co., Ltd. Elastase inhibitor
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
RU95104898A (ru) 1994-03-31 1996-12-27 Бристоль-Мейерз Сквибб Компани (US) Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
WO1997019084A1 (en) 1995-11-23 1997-05-29 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as tachykinin antagonists
AU728373B2 (en) 1995-12-07 2001-01-11 Scripps Research Institute, The HIV protease inhibitors
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
CN1515248A (zh) * 1996-04-23 2004-07-28 ��̩��˹ҩ��ɷ����޹�˾ 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物
US5990276A (en) * 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
ATE320432T1 (de) 1996-09-25 2006-04-15 Merck Sharp & Dohme Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
WO1998015544A1 (en) 1996-10-08 1998-04-16 Colorado State University Research Foundation Catalytic asymmetric epoxidation
EP0932617B1 (en) * 1996-10-18 2002-01-16 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE19648011A1 (de) 1996-11-20 1998-05-28 Bayer Ag Cyclische Imine
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
DE69816280T2 (de) 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
GB9711114D0 (en) 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6183121B1 (en) 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999028482A2 (en) * 1997-11-28 1999-06-10 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
ES2281170T3 (es) * 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
US6251583B1 (en) 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
US6117639A (en) 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
US6025516A (en) 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
US6117870A (en) 1998-11-12 2000-09-12 Fujirebio Kabushiki Kaisha Cyclic amide derivatives
ATE400251T1 (de) 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
US20020042046A1 (en) 1999-02-25 2002-04-11 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
WO2000056331A1 (en) * 1999-03-19 2000-09-28 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
US20020183249A1 (en) 1999-08-31 2002-12-05 Taylor Neil R. Method of identifying inhibitors of CDC25
AU2055301A (en) * 1999-12-03 2001-06-12 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
EP1261611A2 (en) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
ATE297946T1 (de) * 2000-04-03 2005-07-15 Vertex Pharma Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
CN1441806A (zh) 2000-04-05 2003-09-10 先灵公司 包含n－环p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
NZ521456A (en) * 2000-04-19 2004-07-30 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
EP2289888A3 (en) 2000-06-30 2011-07-13 Seikagaku Corporation Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
IL153670A0 (en) 2000-07-21 2003-07-06 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
CZ2003195A3 (cs) 2000-07-21 2003-04-16 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6939692B2 (en) 2000-09-12 2005-09-06 Degussa Ag Nucleotide sequences coding for the pknB gene
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
US6602718B1 (en) * 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
MXPA03004299A (es) 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
JP4848528B2 (ja) * 2000-12-28 2011-12-28 株式会社Ｉｈｉ イオン質量分離方法及び装置、並びにイオンドーピング装置
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
EP1356123A2 (en) 2001-01-30 2003-10-29 Vertex Pharmaceuticals Incorporated A quantitative assay for nucleic acids
WO2002077206A1 (en) 2001-03-27 2002-10-03 Vertex Pharmaceuticals Incorporated Compositiona and methods useful for hcv infection
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
CA2450545A1 (en) 2001-07-03 2003-01-16 Altana Pharma Ag Process for the production of 3-phenylisoserine
WO2003006490A1 (en) 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
JP2003055389A (ja) 2001-08-09 2003-02-26 Univ Tokyo 錯体及びそれを用いたエポキシドの製法
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
MXPA04003825A (es) * 2001-10-24 2004-07-08 Vertex Pharma Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
WO2003048135A1 (en) 2001-11-14 2003-06-12 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7273885B2 (en) 2002-04-11 2007-09-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
TWI328576B (en) 2002-04-25 2010-08-11 Ono Pharmaceutical Co Diketohydrazine derivative compound, medicament containing same as active ingredient
SG174624A1 (en) 2002-08-01 2011-10-28 Pharmasset Inc Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
CA2413705A1 (en) 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
KR100940619B1 (ko) 2003-02-07 2010-02-05 이난타 파마슈티칼스, 인코포레이티드 마크로사이클릭 씨형 간염 세린 단백효소 억제제
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
CA2516328A1 (en) 2003-02-18 2004-09-02 Pfizer Inc. Inhibitors of hepatitis c virus, compositions and treatments using the same
EP1601685A1 (en) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
JP4682140B2 (ja) 2003-03-05 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類縁体
CN1771257A (zh) 2003-04-10 2006-05-10 贝林格尔·英格海姆国际有限公司 通过钌络合物催化的易位反应制备大环化合物的方法
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2004230946A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
CN102020700A (zh) * 2003-07-18 2011-04-20 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1670415A4 (en) 2003-09-12 2007-12-05 Vertex Pharma ANIMAL MODEL FOR STUDYING PROTEASES ACTIVITY AND HEPATIC DISORDERS
AU2004274468B2 (en) 2003-09-18 2009-07-23 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US6933760B2 (en) 2003-09-19 2005-08-23 Intel Corporation Reference voltage generator for hysteresis circuit
AU2004274051A1 (en) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
EP1664092B1 (en) 2003-09-26 2011-02-02 Schering Corporation Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
TW200528472A (en) * 2003-10-10 2005-09-01 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
AR045870A1 (es) 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US20060003942A1 (en) 2003-10-27 2006-01-05 Roger Tung Combinations for HCV treatment
EP1678202B1 (en) 2003-10-27 2012-06-13 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
EP1678134B1 (en) 2003-10-28 2009-09-09 Vertex Pharmaceuticals Incorporated Preparation of 4,5-dialkyl-3-acyl-pyrrole-2-carboxylic acid derivatives by fischer-fink type synthesis and subsequent acylation
US20050119318A1 (en) 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN1902216A (zh) 2003-11-20 2007-01-24 先灵公司 丙肝病毒ns3蛋白酶的去肽化抑制剂
EP1689857A1 (en) 2003-12-01 2006-08-16 Vertex Pharmaceuticals Incorporated Compositions comprising fetal liver cells and methods useful for hcv infection
CN100509784C (zh) 2003-12-11 2009-07-08 先灵公司 丙型肝炎病毒ns3/ns4a丝氨酸蛋白酶的抑制剂
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
EP1711515A2 (en) * 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
BRPI0507861A (pt) 2004-02-20 2007-07-17 Boehringer Ingelheim Int inibidores de polimerase viral
DK1730110T3 (da) 2004-02-27 2010-09-27 Schering Corp Svovlforbindelser som inhibitorer af hepatitis C-virus NS3-serinprotease
TW200529822A (en) 2004-02-27 2005-09-16 Schering Corp Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
EP1737821B1 (en) 2004-02-27 2009-08-05 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
CN1950393A (zh) 2004-02-27 2007-04-18 先灵公司 丙型肝炎病毒ns3蛋白酶的抑制剂
HUE024556T2 (hu) 2004-03-12 2016-02-29 Vertex Pharma Eljárások és intermedierek aszparagin acetál kapszáz inhibitorok elõállítására
US7901707B2 (en) 2004-03-15 2011-03-08 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
PE20060309A1 (es) 2004-05-06 2006-04-13 Schering Corp (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l
ES2328596T3 (es) 2004-05-20 2009-11-16 Schering Corporation Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c.
ZA200700030B (en) * 2004-06-08 2009-06-24 Vertex Pharma Pharmaceutical compositions
WO2006000085A1 (en) 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
CA2538624C (en) 2004-07-02 2009-03-24 The Governors Of The University Of Alberta Aqueous solutions containing .beta.-glucan and gums
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
JP2008511633A (ja) 2004-08-27 2008-04-17 シェーリング コーポレイション Ｃ型肝炎ウィルスｎｓ３セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物
TW201300108A (zh) * 2004-10-01 2013-01-01 Vertex Pharma Ｃ型肝炎病毒（ｈｃｖ）ｎｓ３-ｎｓ４ａ蛋白酶抑制劑
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
DE602006013492D1 (de) * 2005-08-19 2010-05-20 Vertex Pharma Verfahren und zwischenprodukte
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
NZ571280A (en) 2006-03-16 2011-10-28 Vertex Pharma Deuterated hepatitis C protease inhibitors
EP1993993A1 (en) 2006-03-16 2008-11-26 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
EP2001497A4 (en) 2006-03-20 2012-11-07 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
JP2009530415A (ja) 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
US7651520B2 (en) * 2006-05-30 2010-01-26 Ostial Solutions, Llc Means and method for the accurate placement of a stent at the ostium of an artery
MX2008015253A (es) 2006-05-31 2008-12-17 Vertex Pharma Formulaciones de liberacion controlada.
US7708294B2 (en) 2006-11-02 2010-05-04 Gm Global Technology Operations, Inc. Detachable dual-use platform apparatus and method
AU2008219704A1 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7959488B2 (en) * 2007-10-15 2011-06-14 Tania Alessandra Talamo Brassiere pad system

Also Published As

Publication number Publication date
IL191905A0 (en) 2008-12-29
DK0932617T3 (da) 2002-04-22
JP4080541B2 (ja) 2008-04-23
JP5301523B2 (ja) 2013-09-25
NO329751B1 (no) 2010-12-13
AU5147798A (en) 1998-05-15
ZA979327B (en) 1998-05-11
NO991832L (no) 1999-06-17
US8314141B2 (en) 2012-11-20
EP2409985A2 (en) 2012-01-25
UA66767C2 (uk) 2004-06-15
CA2268391A1 (en) 1998-04-30
SK286105B6 (sk) 2008-03-05
US20040266731A1 (en) 2004-12-30
CN1238780A (zh) 1999-12-15
JP2001502694A (ja) 2001-02-27
JP4783353B2 (ja) 2011-09-28
IN183120B (cg-RX-API-DMAC10.html) 1999-09-11
NO20100145L (no) 1998-04-20
ATE212037T1 (de) 2002-02-15
HU227742B1 (en) 2012-02-28
HUP0000152A3 (en) 2000-09-28
US6617309B2 (en) 2003-09-09
PT932617E (pt) 2002-06-28
US20130012430A1 (en) 2013-01-10
IS5028A (is) 1999-04-15
HK1023779A1 (en) 2000-09-22
EA001915B1 (ru) 2001-10-22
BR9712544B1 (pt) 2013-10-22
KR20000049263A (ko) 2000-07-25
NO991832D0 (no) 1999-04-16
TR199901602T2 (xx) 1999-10-21
EP0932617B1 (en) 2002-01-16
TW530065B (en) 2003-05-01
US20020032175A1 (en) 2002-03-14
EA199900388A1 (ru) 1999-12-29
US6265380B1 (en) 2001-07-24
EP2409985A3 (en) 2013-05-01
IL129407A (en) 2008-11-03
JP2008063341A (ja) 2008-03-21
CZ298749B6 (cs) 2008-01-16
JP2011093912A (ja) 2011-05-12
SK51099A3 (en) 2000-04-10
EP0932617A1 (en) 1999-08-04
ES2169880T3 (es) 2002-07-16
PL194025B1 (pl) 2007-04-30
GEP20012471B (en) 2001-06-25
PL192280B1 (pl) 2006-09-29
MXPA05003026A (es) 2005-06-15
US7388017B2 (en) 2008-06-17
EE04023B1 (et) 2003-04-15
KR100509388B1 (ko) 2005-08-23
BG103392A (en) 2000-01-31
AP1019A (en) 2001-10-16
NZ335276A (en) 2000-09-29
PL332872A1 (en) 1999-10-25
AU719984B2 (en) 2000-05-18
UA79749C2 (en) 2007-07-25
CN1133649C (zh) 2004-01-07
AP9901512A0 (en) 1999-06-30
EP2314598A1 (en) 2011-04-27
HUP0000152A2 (en) 2000-07-28
BR9712544A (pt) 1999-10-19
US20090143312A1 (en) 2009-06-04
CZ134099A3 (cs) 1999-08-11
DE69709671D1 (de) 2002-02-21
EE9900161A (et) 1999-12-15
WO1998017679A1 (en) 1998-04-30
ID21649A (id) 1999-07-08
DE69709671T2 (de) 2002-08-22

Similar Documents

Publication Publication Date Title
IL129407A0 (en) Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
HUP0401730A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
AU2933797A (en) Synthetic inhibitors of hepatitis c virus ns3 protease
HUP0303358A3 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
HUP0103806A3 (en) Serine protease inhibitor and pharmaceutical compositions containing them
HUP0002942A3 (en) Peptides having serine protease inhibiting effect pharmaceutical compositions comprising thereof and their use
IL111175A0 (en) Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
GB9707659D0 (en) Hepatitis C NS3 Protease inhibitors
AU2002230763A8 (en) Inhibitors of hepatitis c virus ns3 protease
HUP0400456A3 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties and pharmaceutical compositions containing them
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
HUP0100669A3 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
ATE430166T1 (de) Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
AU4236796A (en) Cysteine protease and serine protease inhibitors
GB9825946D0 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
IL120311A0 (en) Serine protease inhibitors and pharmaceutical compositions containing them
HU9602886D0 (en) Methods of prouducing effective recombinant serine protease inhibitors and uses of these inhibitors
IL120310A0 (en) Serine protease inhibitors and pharmaceutical compositions containing them
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
EP1141255A4 (en) MODIFIED FORMS OF HEPATITIS C VIRUS NS3 PROTEASE
CA2342985A1 (en) Hydroxamate-containing cysteine and serine protease inhibitors
IL112423A0 (en) Inhibitors of serine proteases, their preparation and pharmaceutical compositions containing them
AU2002308200A1 (en) Peptides and their use as inhibitors of hepatitis c virus ns3 protease